Toxicological Studies of (212)Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial

Faced with the novelty of a (212)Pb-labeled monoclonal antibody (mAb) for clinical translation, concerns were expressed by the Food and Drug Administration (FDA) regarding (212)Pb prematurely released from the mAb-chelate conjugate. The objective of this study was to simulate the worst case scenario...

Descripción completa

Detalles Bibliográficos
Autores principales: Milenic, Diane E., Molinolo, Alfredo A., Solivella, María S., Banaga, Eileen, Torgue, Julien, Besnainou, Sarah, Brechbiel, Martin W., Baidoo, Kwamena E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588175/
https://www.ncbi.nlm.nih.gov/pubmed/26213947
http://dx.doi.org/10.3390/ph8030416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588175/
https://www.ncbi.nlm.nih.gov/pubmed/26213947
http://dx.doi.org/10.3390/ph8030416

Ejemplares similares